HIGHLIGHTS
- who: Advance access publication et al. from the Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania have published the article: Radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile?, in the Journal: (JOURNAL)
- what: The authors provide an overview of the published literature on the efficacy and toxicity of radiotherapy (conventional fractionated or radiosurgery) in aggressive highrisk or DA resistant prolactinomas. Radiosurgery and other types of single-fraction stereotactic radiotherapy are generally indicated notably for tumour growth control in cases that progress after standard therapy and surgery,4 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.